Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Affiliations

• ¹ Department of Medicine, Hematology, Oncology, Immunology, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany. neubauer@staff.uni-marburg.de.
• ² Department of Anesthesiology and Intensive Care Medicine, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.
• ³ Department of Medicine, Pulmonary and Critical Care Medicine, University Hospital Giessen and Marburg and Philipps University Marburg, Member of the German Center for Lung Research (DZL), Baldinger Strasse 1, Marburg, Germany.
• ⁴ Department of Medicine, Hematology, Oncology, Immunology, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.
• ⁵ Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, German Center for Lung Research (DZL), Marburg, Germany.
• ⁶ Institute of Virology, University Hospital Giessen and Marburg, and Philipps University Marburg, Hans-Meerwein-Strasse 2, Marburg, Germany.
• ⁷ Department of Diagnostic and Interventional Radiology, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.
• ⁸ Department of Anesthesiology, Critical Care Medicine, Emergency Medicine and Pain Therapy, Klinikum Kassel, Mönchebergstraße 41-43, Kassel, Germany.